Drug Trial Radar · NCT04193527
A Study to Evaluate the Diagnostic Efficacy of DaTSCAN™ Ioflupane (123I) Injection in Single Photon Emission Computed Tomography (SPECT) for the Diagnosis of Parkinsonian Syndrome (PS) in Chinese Patients
Last checked: Nov 20, 2026Latest source record: Oct 16, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
172
Actual
Start
Jun 28, 2020
Primary completion
Dec 20, 2021
Study completion Dec 20, 2021
Sponsor
- Lead sponsor
- GE HealthcareIndustry
- Sponsor type
- Industry
- Collaborators
- PPD Development, LP
- First posted
- Dec 10, 2019
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Diagnostic
- FDA-regulated drug
- No
- Who can join
- All sexes, from 40 years, up to 80 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
This is a multicenter, open-label, non-controlled, non-randomized, phase 3 clinical study to compare the SPECT findings after a single IV administration of DaTSCAN™ ioflupane (123I) injection for patients with a clinical diagnosis of Parkinsonian syndrome (PS) involving striatal dopaminergic deficit (SDD; specifically, Parkinson's disease \[PD\] \[SDD\], multiple system atrophy \[MSA\] \[SDD\] or or progressive supranuclear palsy \[PSP\] \[SDD\]) as compared with patients with a clinical diagnosis of essential tremor (ET) (no SDD) and age-matched healthy controls.
Conditions
- Parkinsonian Syndrome
- Parkinson Disease(PD)
- Multiple System Atrophy (MSA)
- Progressive Supranuclear Palsy (PSP)
- Essential Tremor
Interventions
DaTSCAN™ Ioflupane (123I) InjectionDrug
All participants (Participants with PS, ET, and HV) received a single dose of DaTSCAN™ ioflupane (123I) injection within the range of 111 to 185 megabecquerel (MBq) (3 to 5 millicurie \[mCi\]) per participant at a maximum volume of 5 milliliter \[mL\]) intravenously on Day 1.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Sensitivity Analysis of the Blinded Independent Read of DaTSCAN™ SPECT ImagesTime frame: At Day 1
- Specificity Analysis of the Blinded Independent Read of DaTSCAN™ SPECT ImagesTime frame: At Day 1
Locations
10 sites in 1 country. Site status is shown where the registry gives one.
Peking University First Hospital
Beijing, China
Beijing Friendship Hospital Afflication to Capital Medical University
Beijing, China
Ruijin Hospital, Shanghai Jiaotong University School of Medicine
Shanghai, China
Tianjin Medical University General Hospital
Tianjin, China
Beijing Anzhen Hospital, Capital Medical University
Beijing, Chaoyang District, China
Peking Union Medical College Hospital
Beijing, Dongcheng District, China
Nanfang Hospital, Nanfang Medical Univeristy
Guangdong, Guangzhou, China
Nanjing First Hospital
Nanjing, Jiangsu, China
The Second Affilicated Hospital of Soochow University
Suzhou, Jiangsu, China
Shanghai General Hospital
Hongkou, Shanghai Municipality, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.